Copeptin combined with either non-high sensitivity or high sensitivity cardiac troponin for instant rule-out of suspected non-ST segment elevation myocardial infarction.

CONCLUSION: Findings from a large pooled cohort corroborate the safety of the dual marker strategy for instant rule-out of NSTEMI, extending evidence to hs-cTn. Copeptin below cutoff in combination with hs-cTn below ULN may be used in more than 2.4-times more patients presenting with suspected ACS than a single marker strategy based on very low hs-cTn, without the need to exclude very early presenters or other important subgroups. PMID: 33045866 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33045866?dopt=Abstract

Source: Biomarkers - October 15, 2020 Category: Research Tags: Biomarkers Source Type: research

More News: Heart Attack | Research